Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270939
Substrate
n/a
Meas. Tech.
ChEMBL_552585 (CHEMBL956457)
pH
6±n/a
Kd
320±n/a nM
Comments
extracted
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270939
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-1,2,3-triazol-4-yl)propanamido]-3-phenylpropanamido]-N-methylacetamido}-N-methylacetamido)-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL505609
Type:
Small organic molecule
Emp. Form.:
C69H99N19O16S2
Mol. Mass.:
1514.772
SMILES:
CC(C)C[C@H](N(C)C(=O)CN(C)C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnn[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:47.49,18.26,81.83,100.104,wD:62.65,51.61,43.45,75.79,29.37,4.4,96.101,(23.14,-35.26,;24.48,-36.03,;24.48,-37.57,;25.81,-35.26,;25.81,-33.72,;24.48,-32.95,;23.14,-33.72,;24.48,-31.41,;25.81,-30.64,;23.14,-30.64,;23.14,-29.1,;24.48,-28.33,;21.81,-28.33,;21.81,-26.79,;20.47,-29.1,;19.14,-28.33,;17.81,-29.1,;17.81,-30.64,;16.47,-28.33,;16.47,-26.79,;17.81,-26.02,;17.81,-24.48,;19.14,-23.71,;20.47,-24.48,;20.47,-26.02,;19.14,-26.79,;15.14,-29.1,;13.81,-28.33,;13.81,-26.79,;12.47,-29.1,;12.47,-30.64,;13.4,-31.87,;14.93,-31.84,;15.44,-33.3,;14.21,-34.23,;12.94,-33.34,;11.14,-28.33,;9.81,-29.1,;9.81,-30.64,;8.47,-28.33,;7.13,-29.1,;5.8,-28.33,;5.8,-26.79,;4.46,-29.1,;3.13,-28.33,;1.8,-29.1,;1.8,-30.64,;.46,-28.33,;-.87,-29.1,;-2.2,-28.33,;-2.2,-26.79,;-3.54,-29.1,;-3.54,-30.64,;-2.2,-31.41,;-.87,-30.64,;.46,-31.41,;.46,-32.95,;-.87,-33.72,;-2.2,-32.95,;-4.87,-28.33,;-6.21,-29.1,;-7.55,-28.33,;-6.21,-30.64,;-7.55,-31.41,;-4.87,-31.41,;-4.87,-32.95,;-6.21,-33.72,;-6.21,-35.26,;-7.55,-36.03,;-8.88,-35.26,;-7.55,-37.57,;.46,-26.79,;.45,-25.24,;2,-26.78,;-1.08,-26.8,;4.46,-30.64,;3.13,-31.41,;5.8,-31.41,;27.14,-32.95,;27.14,-31.41,;28.48,-33.72,;29.82,-32.95,;29.82,-31.41,;31.15,-30.64,;32.48,-31.41,;33.82,-30.64,;33.82,-29.1,;35.15,-28.33,;32.48,-28.33,;31.15,-29.1,;31.15,-33.72,;32.48,-32.95,;31.15,-35.26,;29.9,-36.17,;30.38,-37.64,;31.92,-37.64,;32.4,-36.17,;33.68,-35.31,;33.64,-33.77,;35.02,-36.05,;36.34,-35.26,;36.32,-33.72,;34.96,-32.98,;37.69,-36,;39.01,-35.21,;37.71,-37.54,)|
Structure:
Search PDB for entries with ligand similarity: